Mineralys Therapeutics, Inc. SEC filings MLYS
Mineralys Therapeutics, Inc. has 408 filings in SEC EDGAR's recent list, going back to Jun 13, 2022. Its latest annual report, Form ARS, was filed on Apr 10, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations, officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Nov 4, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Oct 29, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 19, 2026 | Oct 16, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 11, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Other events
|
Jun 3, 2026 | Jun 3, 2026 |
| 424B5 | Prospectus supplement | Jun 3, 2026 | — |
| 8-K |
Current report
Material agreement, New debt
|
Jun 3, 2026 | Jun 2, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 22, 2026 | May 21, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 6, 2026 | May 6, 2026 |
| ARS | Annual report to shareholders | Apr 10, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 8, 2026 | — |
| DEF 14A | Proxy statement | Apr 8, 2026 | May 21, 2026 |
| 10-K | Annual report | Mar 12, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 12, 2026 | Mar 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 9, 2026 | Mar 6, 2026 |
| S-8 | Employee stock plan registration | Feb 13, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 6, 2026 | Jan 6, 2026 |
| S-3ASR | Automatic shelf registration | Nov 10, 2025 | — |
| 10-Q | Quarterly report | Nov 10, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2025 | Nov 10, 2025 |
| 8-K |
Current report
Other events
|
Sep 3, 2025 | Sep 2, 2025 |
| 424B5 | Prospectus supplement | Sep 3, 2025 | — |
| S-3MEF | Filing | Sep 2, 2025 | — |
| 8-K |
Current report
Other events
|
Sep 2, 2025 | Sep 2, 2025 |
| 424B5 | Prospectus supplement | Sep 2, 2025 | — |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 17, 2025 | Jun 17, 2025 |
| 8-K |
Current report
Shareholder vote results
|
May 22, 2025 | May 22, 2025 |
| 10-Q | Quarterly report | May 12, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 12, 2025 | May 12, 2025 |
| ARS | Annual report to shareholders | Apr 9, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 9, 2025 | — |
| DEF 14A | Proxy statement | Apr 9, 2025 | May 22, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 31, 2025 | Mar 29, 2025 |
| 8-K |
Current report
Other events
|
Mar 12, 2025 | Mar 11, 2025 |
| 424B5 | Prospectus supplement | Mar 12, 2025 | — |
| 424B5 | Prospectus supplement | Mar 10, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 10, 2025 | Mar 10, 2025 |
| S-8 | Employee stock plan registration | Feb 14, 2025 | — |
| 10-K | Annual report | Feb 12, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 12, 2025 | Feb 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Feb 4, 2025 | Feb 4, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 8, 2025 | Jan 8, 2025 |
| S-8 | Employee stock plan registration | Nov 12, 2024 | — |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2024 | Nov 11, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 30, 2024 | Oct 30, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 25, 2024 | Sep 25, 2024 |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Officer or director change
|
Jun 14, 2024 | Jun 13, 2024 |
| 8-K |
Current report
Other events
|
Jun 10, 2024 | Jun 10, 2024 |
| 8-K | Current report | May 31, 2024 | May 31, 2024 |
| 8-K |
Current report
Shareholder vote results
|
May 22, 2024 | May 22, 2024 |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| EFFECT | Filing | Apr 11, 2024 | — |
| 424B5 | Prospectus supplement | Apr 11, 2024 | — |
| CORRESP | Letter to the SEC | Apr 9, 2024 | — |
| ARS | Annual report to shareholders | Apr 9, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 9, 2024 | — |
| DEF 14A | Proxy statement | Apr 9, 2024 | Apr 9, 2024 |
| 8-K |
Current report
Officer or director change
|
Apr 4, 2024 | Mar 29, 2024 |
| S-3/A | Filing | Mar 29, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2024 | — |
| 8-K |
Current report
Material agreement, Results of operations
|
Mar 21, 2024 | Mar 21, 2024 |
| S-3 | Shelf registration | Mar 21, 2024 | — |
| 10-K | Annual report | Mar 21, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Feb 8, 2024 | Feb 7, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 4, 2024 | Jan 4, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 22, 2023 | Dec 21, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 13, 2023 | Nov 11, 2023 |
| 10-Q | Quarterly report | Nov 7, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2023 | Nov 7, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 2, 2023 | Nov 2, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 14, 2023 | Sep 12, 2023 |
| 10-Q | Quarterly report | Aug 7, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2023 | Aug 7, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 17, 2023 | Jul 17, 2023 |
| 10-Q | Quarterly report | May 15, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 15, 2023 | May 15, 2023 |
| 8-K |
Current report
Other events
|
May 2, 2023 | May 2, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 22, 2023 | Mar 17, 2023 |
| 10-K | Annual report | Mar 15, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 15, 2023 | Mar 15, 2023 |
| SEC STAFF LETTER | Filing | Feb 15, 2023 | — |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Feb 14, 2023 | Feb 14, 2023 |
| S-8 | Employee stock plan registration | Feb 10, 2023 | — |
| 424B4 | Prospectus | Feb 10, 2023 | — |
| EFFECT | Filing | Feb 9, 2023 | — |
| S-1MEF | Filing | Feb 9, 2023 | — |
| CERT | Filing | Feb 9, 2023 | — |
| CORRESP | Letter to the SEC | Feb 7, 2023 | — |
| CORRESP | Letter to the SEC | Feb 7, 2023 | — |
| 8-A12B | Filing | Feb 6, 2023 | — |
| S-1/A | Amended registration statement | Feb 2, 2023 | — |
| S-1 | Registration statement | Jan 18, 2023 | — |
| DRSLTR | Filing | Dec 29, 2022 | — |
| DRS/A | Filing | Dec 29, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 16, 2022 | — |
| DRS/A | Filing | Dec 7, 2022 | — |
| DRSLTR | Filing | Dec 6, 2022 | — |
| SEC STAFF LETTER | Filing | Dec 1, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 1, 2022 | — |
| DRS | Filing | Nov 4, 2022 | — |
| D | Filing | Jun 13, 2022 | — |
Showing 110 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MLYS (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Radnor, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1933414
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.